Literature DB >> 14710890

The Sézary syndrome: hematologic criteria.

Eric C Vonderheid1, Maria Grazia Bernengo.   

Abstract

The hematologic criteria for Sézary syndrome that were recently proposed by the International Society on Cutaneous Lymphomas are critically evaluated. Based on the experience at two institutions, revisions to the definition for Sézary syndrome are proposed.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14710890     DOI： 10.1016/s0889-8588(03)00120-5

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


  11 in total

1.  Alarms and parameters generated by hematology analyzer: new tools to predict and quantify circulating Sezary cells.

Authors:  Gabriel Brisou; Delphine Manzoni; Stephane Dalle; Pascale Felman; Dominique Morel; Marouane Boubaya; Jean Pierre Magaud; Lucile Baseggio
Journal:  J Clin Lab Anal       Date:  2014-03-20       Impact factor: 2.352

2.  Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.

Authors:  Elise A Olsen; Sean Whittaker; Youn H Kim; Madeleine Duvic; H Miles Prince; Stuart R Lessin; Gary S Wood; Rein Willemze; Marie-France Demierre; Nicola Pimpinelli; Maria Grazia Bernengo; Pablo L Ortiz-Romero; Martine Bagot; Teresa Estrach; Joan Guitart; Robert Knobler; José Antonio Sanches; Keiji Iwatsuki; Makoto Sugaya; Reinhard Dummer; Mark Pittelkow; Richard Hoppe; Sareeta Parker; Larisa Geskin; Lauren Pinter-Brown; Michael Girardi; Günter Burg; Annamari Ranki; Maartan Vermeer; Steven Horwitz; Peter Heald; Steve Rosen; Lorenzo Cerroni; Brigette Dreno; Eric C Vonderheid
Journal:  J Clin Oncol       Date:  2011-05-16       Impact factor: 44.544

3.  Cutaneous T-cell lymphoma (CTCL): Current practices in blood assessment and the utility of T-cell receptor (TCR)-Vβ chain restriction.

Authors:  Juliet F Gibson; Jing Huang; Kristina J Liu; Kacie R Carlson; Francine Foss; Jaehyuk Choi; Richard Edelson; Jerry W Hussong; Ramsey Mohl; Sally Hill; Michael Girardi
Journal:  J Am Acad Dermatol       Date:  2016-02-10       Impact factor: 11.527

Review 4.  Immunopathogenesis and therapy of cutaneous T cell lymphoma.

Authors:  Ellen J Kim; Stephen Hess; Stephen K Richardson; Sara Newton; Louise C Showe; Bernice M Benoit; Ravi Ubriani; Carmela C Vittorio; Jacqueline M Junkins-Hopkins; Maria Wysocka; Alain H Rook
Journal:  J Clin Invest       Date:  2005-04       Impact factor: 14.808

5.  Loss of nuclear pro-IL-16 facilitates cell cycle progression in human cutaneous T cell lymphoma.

Authors:  Clara Curiel-Lewandrowski; Hisato Yamasaki; Chuan Ping Si; Xiaoyi Jin; Yujun Zhang; Jillian Richmond; Marina Tuzova; Kevin Wilson; Beth Sullivan; David Jones; Nataliya Ryzhenko; Frederick Little; Thomas S Kupper; David M Center; William W Cruikshank
Journal:  J Clin Invest       Date:  2011-11-14       Impact factor: 14.808

Review 6.  Mycosis fungoides and sezary syndrome: an update.

Authors:  Ellen J Kim; Julie Lin; Jacqueline M Junkins-Hopkins; Carmela C Vittorio; Alain H Rook
Journal:  Curr Oncol Rep       Date:  2006-09       Impact factor: 5.075

7.  High-scatter T cells: a reliable biomarker for malignant T cells in cutaneous T-cell lymphoma.

Authors:  Rachael A Clark; Jeffrey B Shackelton; Rei Watanabe; Adam Calarese; Kei-ichi Yamanaka; James J Campbell; Jessica E Teague; Helen P Kuo; DirkJan Hijnen; Thomas S Kupper
Journal:  Blood       Date:  2010-12-09       Impact factor: 22.113

8.  Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.

Authors:  Richard L Piekarz; Robin Frye; Maria Turner; John J Wright; Steven L Allen; Mark H Kirschbaum; Jasmine Zain; H Miles Prince; John P Leonard; Larisa J Geskin; Craig Reeder; David Joske; William D Figg; Erin R Gardner; Seth M Steinberg; Elaine S Jaffe; Maryalice Stetler-Stevenson; Stephen Lade; A Tito Fojo; Susan E Bates
Journal:  J Clin Oncol       Date:  2009-10-13       Impact factor: 44.544

9.  Romidepsin in the treatment of cutaneous T-cell lymphoma.

Authors:  Salvia Jain; Jasmine Zain
Journal:  J Blood Med       Date:  2011-04-04

10.  Erythroderma: review of a potentially life-threatening dermatosis.

Authors:  Cynthia Okoduwa; W C Lambert; R A Schwartz; E Kubeyinje; A Eitokpah; Smeeta Sinha; W Chen
Journal:  Indian J Dermatol       Date:  2009       Impact factor: 1.494
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.